Tag Archives: TecentriqAvastin

Roche’s Tecentriq-Avastin lung cancer combo gets a lift from England’s cost watchdogs

Roche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lung cancer. The National Institute of Health and Care Excellence (NICE) decided to back the immuno-oncology drug, in combination with Roche’s Avastin and chemo,… Read More »